AD

Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

Logo Benzinga
Benzinga
By Business Wire

Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds

AD
AD

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (SNSNN, the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed.

The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). Having previously been approved for the Swiss market, Healiva's® acquisition of the complete product dossier should enable the rapid market re-launch of EpiDex®.

The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy that has previously demonstrated clinical efficacy in healing VLUs that are resistant to standard treatments.

We created Healiva® to improve the lives of the millions suffering from chronic wounds by delivering innovative, effective new treatments to patients, said Healiva's® Founder and CEO, Priyanka Dutta-Passecker, PhD, MBA. These remarkable cell therapies will make a pivotal contribution to that mission by addressing crucial needs in early- and late-stage chronic wound care. By adding these pioneering technologies to our growing portfolio of wound treatments, we will be able to continue our rapid growth by progressing to commercialization within four years of founding.

Continue read on benzinga.com

AD
Logo Benzinga
NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines...

Logo Benzinga
The Cell Therapy Global Market Report 2022: By Technique, By Therapy, By Application report has been added to ResearchAndMarkets.com's offering. The global...

Logo Benzinga
New York, May 10, 2024 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report Global Negative Pressure Wound Therapy (NPWT) Industry -...

Logo Benzinga
Clinical-stage biotech to implement a unified platform with a single data fabric versus point solutions AUSTIN, Texas, May 31, 2024 /PRNewswire/ -- L7...

Logo Benzinga
MediWound Ltd MDWD has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). The study met its...

Logo Benzinga
New York, May 27, 2024 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on Single-Use Negative Pressure Wound Therapy Devices Market...

Logo Benzinga
NEW YORK, May 11, 2024 /PRNewswire/ -- As per Zion Market Research study, Advanced Wound Care Market was worth around USD 9,215.1 million in 2021 and is...

Logo Benzinga
Newark, NJ, May 19, 2024 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, The global stem cells market is expected to grow from USD 1.15...

Logo Benzinga
The Global Wound Closure Market - Forecasts from 2022 to 2027 report has been added to ResearchAndMarkets.com's offering. The global wound closure market was...

Logo Benzinga
DUBLIN, May 16, 2024 /PRNewswire/ --The Global Wound Closure Market - Forecasts from 2022 to 2027 report has been added to ResearchAndMarkets.com's offering....

Logo Benzinga
DUBLIN, May 20, 2024 /PRNewswire/ --The Negative Pressure Wound Therapy (NPWT) - Global Market Trajectory & Analytics report has been added to...

Logo Benzinga
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The Global Wound Closure Market - Forecasts from 2022 to 2027 report has been added to ResearchAndMarkets.com's...

Logo Benzinga
FRAMINGHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. ARTH ( Arch or the Company ), a marketer and developer of novel self-assembling...

Logo Benzinga
New York, May 30, 2024 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report Biofilms Treatment Market Research Report by Product, Wound...

Logo Benzinga
RestorixHealth is pleased to announce that Brooke Gautreaux, FNP-C, has joined RestorixHealth as an At-Home Wound Healing Services wound care provider in...

Logo Benzinga
The Digital Wound Measurement Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Type of Wound, Device Type, Application and...

Logo Benzinga
Wound care biologics are one of the prime popular treatments for burns since they allow for a quick recovery with few or no problems and act as the major key...

Logo Benzinga
BERKELEY, Calif., May 11, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company,...

Logo Benzinga
Ocugen Inc OCGN says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived...

Logo PR Newswire
Clinical-stage biotech to implement a unified platform with a single data fabric versus point solutions AUSTIN, Texas, May 31, 2024 /PRNewswire/ -- L7...